Fasinumab, nerve growth factor inhibitor, studied in a phase II trial of 421 moderate-to-severe OA (knee or hip) pts x36 wks & show to be better than placebo. But FAS had more AE (17% v 10%), Jt Surgeries (7% v 1%) and destructive arthropathy in 1 FAS pt https://t.co/eHvYrByF1Z